BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Advanced solid tumors clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for advanced solid tumors: 1599 (518 sponsors; 133 newly posted in the last 180 days, 73 stopped in the last 180 days; 53 new-entrant sponsors). Momentum score 4.6, rank 89 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 14, Phase 1 536, Phase 2 430, Phase 3 4, Phase 4 0, N/A 16.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 20 | P2 14, P1 5, P3 1 | 1 | 1 |
| Hutchmed HCM | 2 | P2 1, P3 1 | 0 | 0 |
| Intra-IMMUSG Pte Ltd | 2 | P2 1, P3 1 | 0 | 1 |
| SUNHO(China)BioPharmaceutical CO., Ltd. | 2 | P3 1, P2 1 | 0 | 0 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 26 | P1 20, P2 6 | 9 | 3 |
| Bristol-Myers Squibb BMY | 12 | NA 1, P2 5, P1 6 | 0 | 1 |
| Jiangsu HengRui Medicine Co., Ltd. | 12 | P2 8, P1 4 | 0 | 2 |
| Merck Sharp & Dohme LLC MRK | 12 | P2 10, P1 2 | 4 | 1 |
| Qilu Pharmaceutical Co., Ltd. | 12 | P2 7, P1 5 | 2 | 3 |
| CSPC Megalith Biopharmaceutical Co.,Ltd. | 10 | P2 5, P1 4, NA 1 | 4 | 2 |
| Hansoh BioMedical R&D Company | 10 | P1 8, P2 2 | 2 | 0 |
| MediLink Therapeutics (Suzhou) Co., Ltd. | 10 | P2 7, P1 3 | 0 | 4 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | 10 | P1 5, P2 5 | 0 | 3 |
| BeOne Medicines ONC | 9 | P1 8, P2 1 | 2 | 1 |
| Innovent Biologics (Suzhou) Co. Ltd. | 9 | P2 5, P1 4 | 2 | 1 |
| LaNova Medicines Limited | 9 | P2 9 | 3 | 1 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 9 | P2 5, P1 4 | 0 | 0 |
| Daiichi Sankyo | 8 | P1 4, P2 4 | 2 | 1 |
| Eli Lilly and Company LLY | 8 | P1 7, P2 1 | 0 | 1 |
| Boehringer Ingelheim | 7 | P1 6, P2 1 | 3 | 1 |
| Exelixis EXEL | 7 | P1 7 | 0 | 3 |
| GlaxoSmithKline | 7 | P2 3, P1 4 | 2 | 1 |
| Novartis Pharmaceuticals NVS | 7 | P1 3, P2 3, NA 1 | 1 | 3 |
| Pfizer PFE | 7 | P1 5, P2 2 | 1 | 1 |
| Shanghai Henlius Biotech | 7 | P1 6, EARLY_P1 1 | 1 | 3 |
Recently stopped trials
- NCT06772415 Changchun GeneScience Pharmaceutical Co., Ltd. - terminated: The sponsor adjusted its research and development strategy A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants Wi
- NCT05462873 Novartis Pharmaceuticals - terminated: Business decision and not related to safety concerns A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
- NCT04241835 Epizyme, Inc. - terminated: Sponsor's decision to discontinue tazemetostat treatment based on emerging safety data from another clinical trial indicating there may be a A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe
- NCT06107894 NeogenTC - terminated: It is due to difficulties in enrolling participants. TIL Therapy for Patients With Advanced Solid Tumors
- NCT05155332 Boehringer Ingelheim - suspended: Sponsor decision - temporary enrolment hold as a precautionary measure following a safety event. A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe
- NCT06756035 Context Therapeutics Inc. - terminated: The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termi CT-95 in Advanced Cancers Associated With Mesothelin Expression
- NCT06573294 Genmab - terminated: Genmab has decided to terminate the GEN1057 program due to marginal anti-tumor activity not supporting further development Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
- NCT06171789 Genmab - terminated: Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation PRO1107 in Patients With Advanced Solid Tumors
- NCT02875548 Epizyme, Inc. - terminated: Sponsor decision; no additional participant enrollment was anticipated. A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazem
- NCT04868877 Merus B.V. - terminated: The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-r Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Soli
- NCT06364696 Astellas Pharma Inc - terminated: Company's strategic decision A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
- NCT05358249 Novartis Pharmaceuticals - terminated: Business reasons and not based on any safety concerns. Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
- NCT05382325 Merck Sharp & Dohme LLC - terminated: Business Reasons A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors
- NCT05879822 Incyte Corporation - terminated: This was a strategic business decision. There were no safety concerns contributing to this decision. A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
- NCT05800964 Amgen - terminated: Sponsor decision Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-24 est. | P3 | EMD Serono Research & Development Institute, Inc. | NCT03815643 Avelumab Program Rollover Study | Solid Tumors | active not recruiting | 205 |
| 2026-11-30 est. | P1/P2 | Amgen AMGN | NCT05094336 A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | Advanced MTAP-null Solid Tumors | active not recruiting | 329 |
| 2026-11-30 est. | P1/P2 | Bio-Thera Solutions | NCT06341114 A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Pa | Advanced Solid Tumors | active not recruiting | 112 |
| 2026-12 est. | P1/P2 | 3D Medicines (Sichuan) Co., Ltd. | NCT05024214 Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | Solid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma | recruiting | 170 |
| 2026-12 est. | P1/P2 | Nanjing Leads Biolabs Co.,Ltd | NCT05170958 A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors | Advanced Solid Tumor | recruiting | 396 |
| 2026-12 est. | P1/P2 | Rottapharm Biotech | NCT05205330 Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | Refractory Metastatic Colorectal Cancer; Solid Tumor; Metastatic Microsatellite-stable Colorectal Ca | active not recruiting | 107 |
| 2026-12 est. | P1/P2 | AP Biosciences Inc. | NCT05473156 A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion | Locally Advanced or Metastatic Solid Tumors; Non Small Cell Lung Cancer (NSCLC); Head and Neck Squam | recruiting | 168 |
| 2026-12 est. | P1/P2 | Monte Rosa Therapeutics, Inc GLUE | NCT05546268 Study of Oral MRT-2359 in Selected Cancer Patients | NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC | active not recruiting | 174 |
| 2026-12 est. | P1/P2 | Akeso | NCT05689853 Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors | Solid Tumor, Adult | recruiting | 87 |
| 2026-12 est. | P1/P2 | A2 Biotherapeutics Inc. | NCT05736731 A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression | Solid Tumor, Adult; Solid Tumor; Pancreatic Cancer; Pancreatic Neoplasms; Pancreas Cancer; Non Small | active not recruiting | 160 |
| 2026-12 est. | P1/P2 | TiumBio Co., Ltd. | NCT05784688 Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | Solid Tumor; Biliary Tract Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer | recruiting | 140 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05785039 A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors | Urinary System Tumor; Solid Tumor | recruiting | 76 |
| 2026-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05803018 A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies | Gynecological Malignant Tumor; Solid Tumor | recruiting | 38 |
| 2026-12 est. | P1/P2 | Guangzhou Gloria Biosciences Co., Ltd. | NCT05909436 Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors | Solid Tumor | recruiting | 107 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05965856 A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | Urothelial Carcinoma; Solid Tumor | recruiting | 52 |
| 2026-12 est. | P1/P2 | Xenothera SAS | NCT06154291 FIH XON7 in Advanced/Metastatic Solid Tumors | Advanced Solid Tumor; Metastatic Cancer | recruiting | 255 |
| 2026-12 est. | P1/P2 | Alyssum Therapeutics | NCT06234098 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refra | Solid Tumor | recruiting | 100 |
| 2026-12 est. | P1/P2 | Latticon Antibody Therapeutics, Inc | NCT06277219 A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) | Advanced Solid Tumor | recruiting | 150 |
| 2026-12 est. | P1/P2 | 858 Therapeutics, Inc. | NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovar | recruiting | 120 |
| 2026-12 est. | P1/P2 | Georgiamune Inc | NCT06425926 Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | Melanoma Stage IV; Solid Tumor | recruiting | 117 |
| 2026-12 est. | P1/P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06605222 A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 201 |
| 2026-12 est. | P1/P2 | Akeso | NCT06943820 AK129 Combination Therapy for Advanced Solid Tumors | Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal | recruiting | 230 |
| 2026-12 est. | P2 | Ryvu Therapeutics SA | NCT06987058 RVU120 Rollover Study | Advanced Solid Tumors; Acute Myeloid Leukaemia (AML); High-risk Myelodysplastic Syndrome | enrolling by invitation | 14 |
| 2026-12 est. | P1/P2 | One-carbon Therapeutics AB | NCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | Solid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck; Non-Small Cell Lung | recruiting | 43 |
| 2026-12 est. | P1/P2 | Heron Neutron Medical Corp. | NCT07691775 A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors | Solid Tumor | recruiting | 30 |
| 2026-12-01 est. | P2 | Intra-IMMUSG Pte Ltd | NCT04452955 A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors | Solid Tumor | active not recruiting | 51 |
| 2026-12-01 est. | P2 | EpicentRx, Inc. | NCT04673942 A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors | Solid Tumor, Adult; Cancer; Neoplasms; Sarcoma; Sarcoma,Soft Tissue; Chondrosarcoma | active not recruiting | 140 |
| 2026-12-01 est. | P1/P2 | FindCure Biosciences (ZhongShan) Co., Ltd. | NCT06499350 A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors | Advanced Malignant Solid Tumors | recruiting | 33 |
| 2026-12-01 est. | P1/P2 | AP Biosciences Inc. | NCT06669975 A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors | Advanced Solid Tumor | recruiting | 85 |
| 2026-12-05 est. | P1/P2 | Suzhou Forlong Biotechnology Co., Ltd | NCT07131202 A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 130 |
| 2026-12-15 est. | P1/P2 | PMV Pharmaceuticals, Inc PMVP | NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung C | recruiting | 300 |
| 2026-12-15 est. | P1/P2 | GV20 Therapeutics | NCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | Solid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC); Squamous Head and Neck Carcinoma; | recruiting | 365 |
| 2026-12-24 est. | P2 | Nanjing Leads Biolabs Co.,Ltd | NCT06783647 A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] | Advanced Solid Tumour | recruiting | 250 |
| 2026-12-30 est. | P2 | 3D Medicines (Sichuan) Co., Ltd. | NCT03667170 KN035 for dMMR/MSI-H Advanced Solid Tumors | Solid Tumor | active not recruiting | 188 |
| 2026-12-30 est. | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05631262 SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors | Selected Subjects With Advanced Solid Tumors | active not recruiting | 321 |
| 2026-12-30 est. | P1/P2 | Suzhou Abogen Biosciences Co., Ltd. | NCT06088004 Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors | Solid Tumor, Adult | recruiting | 218 |
| 2026-12-30 est. | P1/P2 | L & L Bio Co., Ltd., Ningbo, China | NCT06468358 A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors | Solid Tumor | recruiting | 194 |
| 2026-12-30 est. | P3 | Jiangsu vcare pharmaceutical technology co., LTD | NCT06658353 Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors | Locally Advanced Solid Tumor | recruiting | 54 |
| 2026-12-31 est. | P2 | Partner Therapeutics, Inc. | NCT02912949 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion; Pancreatic Cancer Harboring NRG1 F | active not recruiting | 250 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P1/P2 | BicycleTx Limited | NCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Advanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Cancer | active not recruiting | 288 |
| 2026-12-31 est. | P3 | Pfizer PFE | NCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors | active not recruiting | 77 |
| 2026-12-31 est. | P1/P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05265091 A Study of KL590586 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | active not recruiting | 414 |
| 2026-12-31 est. | P1/P2 | Impact Therapeutics, Inc. IBO | NCT05269316 Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | Solid Tumor; Advanced Solid Tumor | recruiting | 61 |
| 2026-12-31 est. | P1/P2 | AskGene Pharma, Inc. | NCT05867420 A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | Advanced Solid Tumors | recruiting | 594 |
| 2026-12-31 est. | P1/P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05944224 A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. | Advanced Solid Tumors | recruiting | 63 |
| 2026-12-31 est. | P2 | Allist Pharmaceuticals, Inc. | NCT06008288 A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. | KRAS P.G12C; Pancreatic Cancer; Solid Tumor | recruiting | 88 |
| 2026-12-31 est. | P1/P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT06214143 A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 68 |
| 2026-12-31 est. | P1/P2 | Evopoint Biosciences Inc. | NCT06799637 Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | Advanced Solid Tumors; Pancreatic Carcinoma; Ovarian Cancer; Cervical Cancers | recruiting | 350 |
| 2026-12-31 est. | P1/P2 | Jacobio Pharmaceuticals Co., Ltd. | NCT06959615 A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration | Advanced Solid Tumor | recruiting | 334 |
| 2026-12-31 est. | P1/P2 | Shanghai Cell Therapy Group Co.,Ltd | NCT07146672 Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors | Solid Tumor Cancer | recruiting | 12 |
| 2027-01 est. | P1/P2 | BicycleTx Limited | NCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Urinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Hormone Receptor Positive, HER2-negative | active not recruiting | 329 |
| 2027-01 est. | P1/P2 | LigaChem Biosciences, Inc. | NCT05941507 A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 300 |
| 2027-01 est. | P1/P2 | Jacobio Pharmaceuticals Co., Ltd. | NCT06386146 JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | Solid Tumors | recruiting | 144 |
| 2027-01 est. | P1/P2 | CStone Pharmaceuticals | NCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 800 |
| 2027-01 est. | P1/P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT07208773 A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | Advanced Solid Tumors; Non Small Cell Lung Cancer; Small Cell Lung Cancer | recruiting | 260 |
| 2027-01 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT07298772 A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors | Advanced Solid Tumor | recruiting | 198 |
| 2027-01-16 est. | P1/P2 | Corbus Pharmaceuticals Inc. CRBP | NCT06265727 A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | Solid Tumor, Adult | recruiting | 348 |
| 2027-01-19 est. | P1/P2 | Sanofi SNY | NCT05584670 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Solid Tumor | recruiting | 542 |
| 2027-01-23 est. | P1/P2 | Egle Therapeutics | NCT06622486 First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors | Solid Tumor, Adult | recruiting | 50 |
| 2027-01-25 est. | P1/P2 | Novartis Pharmaceuticals NVS | NCT04699188 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lung | active not recruiting | 344 |
| 2027-01-29 est. | P1/P2 | IDEAYA Biosciences IDYA | NCT03947385 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors | recruiting | 336 |
| 2027-01-30 est. | P1/P2 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT06132217 A Study of Simmitinib Plus SG001 in Advanced Solid Tumors | Advanced Solid Tumor | not yet recruiting | 168 |
| 2027-01-30 est. | P1/P2 | Psivac Ltd | NCT06549946 Ixovex-1 Single Agent and Combination Therapy | Solid Tumor; Head and Neck Cancer | recruiting | 18 |
| 2027-01-31 est. | P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT07202364 A Study of YL202 in Patients With Advanced Solid Tumors | Non Small Cell Lung Cancer; Colorectal Cancer; Cervical Cancer; Locally Advanced or Metastatic Solid | recruiting | 100 |
| 2027-02 est. | P1/P2 | Krystal Biotech, Inc. KRYS | NCT06228326 A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Lung Cancer, Non-small Cell; Lung Cancer Metastatic; Solid Tumor, Adult; Advanced Cancer; Lung Cance | recruiting | 250 |
| 2027-02 est. | P1/P2 | DualityBio Inc. | NCT06554795 First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | Solid Tumor, Adult | recruiting | 360 |
| 2027-02 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT07136142 A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors | Malignant Solid Tumor | recruiting | 150 |
| 2027-02 est. | P1/P2 | GI Innovation, Inc. | NCT07172802 A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor; Metastatic Solid Tumor; Non-small Cell Lung Cancer (NSCLC); Head and Neck (HNS | recruiting | 102 |
| 2027-02-01 est. | P2 | Novartis Pharmaceuticals NVS | NCT02934568 Ribociclib (LEE011) Rollover Study for Continued Access | Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Can | active not recruiting | 22 |
| 2027-02-10 est. | P2 | AstraZeneca AZN | NCT06271837 A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors | Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) | active not recruiting | 127 |
| 2027-02-14 est. | P1/P2 | Beijing Biotech | NCT07589530 Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors | Advanced Solid Tumors; Metastatic Solid Tumors; TROP2-Expressing Solid Tumors | recruiting | 60 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-13 est. | P1/P2 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT06682611 Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. | Unresectable Locally Advanced or Metastatic Solid Tumors | not yet recruiting | 380 |
| 2026-11-13 est. | P1/P2 | Regeneron Pharmaceuticals REGN | NCT04626635 A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | Advanced Solid Tumors | active not recruiting | 548 |
| 2026-11-01 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05584800 Study of ZGGS18 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | recruiting | 222 |
| 2026-11 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06737731 A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors | Malignant Solid Tumors | recruiting | 300 |
| 2026-11 est. | P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT06107686 A Study of YL202 in Selected Patients With Advanced Solid Tumors | NSCLC; Breast Cancer; HNSCC; Locally Advanced or Metastatic Solid Tumors | recruiting | 200 |
| 2026-11 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06015048 A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. | HER2-expressing Advanced Solid Tumors | recruiting | 364 |
| 2026-11 est. | P1/P2 | Tyra Biosciences, Inc TYRA | NCT05544552 Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor; Urothelial Carc | active not recruiting | 310 |
| 2026-11 est. | P1/P2 | Anbogen Therapeutics, Inc. | NCT05532696 Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients | Advanced Solid Tumor; Non Small Cell Lung Cancer; HER2 Mutations | recruiting | 61 |
| 2026-11 est. | P2 | BeiGene | NCT03736889 Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors | MSI-H/dMMR Solid Tumors | recruiting | 200 |
| 2026-10-31 est. | P1/P2 | LaNova Medicines Limited | NCT05518045 A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors | Advanced Solid Tumor | active not recruiting | 392 |
| 2026-10-30 est. | P1/P2 | Shanghai Henlius Biotech | NCT06848699 A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors | Solid Tumor Cancer; Non Small Cell Lung Cancer | recruiting | 105 |
| 2026-10-30 est. | P1/P2 | Nouscom SRL | NCT04041310 Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Solid Tumor, Adult | active not recruiting | 115 |
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-10-01 est. | P2 | Taiho Oncology, Inc. | NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Ade | active not recruiting | 53 |
| 2026-10 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT07256782 A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors | Advanced Solid Tumor | recruiting | 444 |
| 2026-10 est. | P1/P2 | Shanghai Shengdi Pharmaceutical Co., Ltd | NCT07231211 A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors | Solid Tumors | recruiting | 258 |
| 2026-10 est. | P1/P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT06057922 A Study YL201 in Patients With Selected Advanced Solid Tumors | Advanced Solid Tumor | active not recruiting | 990 |
| 2026-10 est. | P2 | Gilead Sciences GILD | NCT05119907 Study of Sacituzumab Govitecan in Patients With Solid Tumor | Solid Tumor | active not recruiting | 53 |
| 2026-10 est. | P1/P2 | Laminar Pharmaceuticals | NCT04299191 Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | High-grade Glioma; Solid Tumor, Unspecified, Child | recruiting | 28 |
| 2026-10 est. | P1/P2 | Immunocore Ltd IMCR | NCT04262466 Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Select Advanced Solid Tumors | active not recruiting | 410 |
| 2026-09-30 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT05888831 A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | Advanced Solid Tumors | active not recruiting | 100 |
| 2026-09-30 | P2 | Incyte Corporation INCY | NCT05879822 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Advanced Solid Tumor | terminated | 73 |
| 2026-09-30 est. | P1/P2 | Turning Point Therapeutics, Inc. TPB | NCT04094610 A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Locally Advanced Solid Tumors; Metastatic Solid Tumors; Lymphoma; Primary CNS Tumors | recruiting | 75 |
| 2026-09-28 | P1/P2 | Novartis Pharmaceuticals NVS | NCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-S | terminated | 74 |
| 2026-09-22 | P1/P2 | Tango Therapeutics, Inc. TNGX | NCT05887492 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Non Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer; Lung Adenocarcinoma | active not recruiting | 126 |
| 2026-09-22 est. | P1/P2 | ImmVira Pharma Co. Ltd | NCT04370587 A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Me | Solid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLC | recruiting | 30 |
| 2026-09-05 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT06730750 A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors | Advanced Solid Tumors | active not recruiting | 360 |
| 2026-09-01 est. | P1/P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT07169994 A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | Advanced Solid Tumors; Breast Cancer; Non Small Cell Lung Cancer | recruiting | 414 |
| 2026-09-01 est. | P1/P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT05990452 Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | active not recruiting | 261 |
| 2026-09 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT06949761 A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced So | Solid Tumor | not yet recruiting | 240 |
| 2026-09 est. | P1/P2 | Shanghai HyaMab Biotech Co.,Ltd. | NCT05801237 PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor | Locally Advanced/Metastatic Solid Tumors | recruiting | 120 |
| 2026-08-30 est. | P1/P2 | Fujian Haixi Pharmaceuticals Co., Ltd. | NCT06220318 Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors | Solid Tumor | active not recruiting | 155 |
| 2026-08-01 est. | P1/P2 | OncoResponse, Inc. | NCT06090266 A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Cancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Cutaneous Melanom | recruiting | 168 |
| 2026-08 est. | P1/P2 | Jacobio Pharmaceuticals Co., Ltd. | NCT05490472 JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | Solid Tumors; ER+ Breast Cancer; Triple Negative Breast Cancer, TNBC; ARID1A Gene Mutation; Small Ce | recruiting | 102 |
| 2026-08 est. | P1/P2 | Treadwell Therapeutics, Inc | NCT05251714 CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | Advanced Solid Tumor; Breast Cancer | active not recruiting | 44 |
| 2026-08 est. | P1/P2 | BicycleTx Limited | NCT05163041 Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | Advanced Solid Tumor | active not recruiting | 200 |
| 2026-08 est. | P1/P2 | Allist Pharmaceuticals, Inc. | NCT05009329 A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China | NSCLC; Solid Tumor | active not recruiting | 315 |
| 2026-07-31 est. | P1/P2 | NEC Bio B.V | NCT06631079 Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors | Solid Tumor | active not recruiting | 20 |
| 2026-07-31 est. | P2 | Hansoh BioMedical R&D Company | NCT06112704 HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors | Advanced Solid Tumor | recruiting | 220 |
| 2026-07-30 est. | P1/P2 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | NCT05744427 Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors | Advanced Solid Tumor | active not recruiting | 725 |
| 2026-07-29 | P1/P2 | Incyte Corporation INCY | NCT06873789 A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors | Solid Tumors; Advanced Solid Tumors; Metastatic Solid Tumors | terminated | 9 |
| 2026-07-28 est. | P1/P2 | Lantern Pharma Inc. LTRN | NCT05933265 Study of LP-184 in Patients With Advanced Solid Tumors | Advanced Solid Tumor; Metastatic Solid Tumor; GBM; TNBC - Triple-Negative Breast Cancer; NSCLC; Panc | active not recruiting | 64 |
| 2026-07-22 | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT06233292 A Study of ZG005 in Patients With Advanced Solid Tumors | Solid Tumors | completed | 125 |
| 2026-07-01 | P1/P2 | Erasca, Inc. ERAS | NCT04866134 A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | completed | 85 |
| 2026-07 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT07102004 Study of MHB088C for Patients With Advanced Solid Malignant Tumors | Advanced/Metastatic Solid Tumors | recruiting | 515 |
| 2026-07 est. | P1/P2 | CJ Bioscience, Inc. | NCT05877430 Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | NSCLC; HNSCC; Melanoma; Metastatic Cancer; Advanced Solid Tumor; Advanced Cancer | recruiting | 160 |
| 2026-06-30 est. | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06974812 IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | 250 |
| 2026-06-30 est. | P1/P2 | Multitude Therapeutics Inc. | NCT06782334 AMT-116 in Patients with Solid Tumors | Advanced Solid Tumors | recruiting | 144 |
| 2026-06-30 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT06446388 Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors | Advanced Solid Tumor | not yet recruiting | 360 |
| 2026-06-30 est. | P1/P2 | LaNova Medicines Limited | NCT06187402 A Study of LM-24C5 For Advanced Solid Tumors | Advanced Solid Tumor | recruiting | 49 |
| 2026-06-30 est. | P1/P2 | TiumBio Co., Ltd. | NCT05204862 Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors | Advanced Solid Tumor | recruiting | 240 |
| 2026-06-30 | P1/P2 | Novita Pharmaceuticals, Inc. | NCT05023486 NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | Advanced or Metastatic Solid Tumor Malignancies | completed | 121 |
| 2026-06-30 | P1/P2 | Linnaeus Therapeutics, Inc. | NCT04130516 Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Solid Tumor, Adult | active not recruiting | 200 |
| 2026-06-22 est. | P1/P2 | GlaxoSmithKline | NCT06710847 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Partic | Neoplasms, Colorectal; Solid Tumor; Colon Cancer; Rectal Cancer; Endometrial Cancer | active not recruiting | 14 |
| 2026-06-22 | P1/P2 | Anaveon AG | NCT06470763 A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) | Advanced Solid Tumor | completed | 63 |
| 2026-06-08 | P2 | Merck Sharp & Dohme LLC MRK | NCT04123366 Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Re | Solid Tumors | completed | 333 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
| 2026-06-02 | P1/P2 | Binhui Biopharmaceutical Co., Ltd. | NCT04386967 OH2 Injection in Solid Tumors | Solid Tumor; Melanoma | completed | 44 |
| 2026-06-01 est. | P2 | Intra-IMMUSG Pte Ltd | NCT07541001 PRL3-Zumab in Patients With Advanced Solid Tumors | Advanced Malignant Solid Tumor | active not recruiting | 60 |
| 2026-06 est. | P2 | AlaMab Therapeutics (Shanghai) Inc. | NCT06416358 A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed | Advanced Solid Tumors With Bone Only Metastasis | not yet recruiting | 144 |
| 2026-06 est. | P1/P2 | Volastra Therapeutics, Inc. | NCT05902988 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Advanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancer | recruiting | 200 |
| 2026-06 est. | P1/P2 | 1ST Biotherapeutics, Inc. | NCT05761223 A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | Advanced Solid Tumor | recruiting | 151 |
| 2026-05-29 | P1/P2 | Amgen AMGN | NCT03600883 A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (Cod | KRAS p.G12C Mutant Advanced Solid Tumors | completed | 713 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "advanced solid tumors"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.